Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Receive an affordable massage at home and on-demand by easily booking straight from an app. Since the start of year, Urban Massage has delivered more than 114,000 massages and received a 4.85/5 or above rating for the level of treatment provided to their customers. The company has successfully launched in Birmingham, Manchester and Paris with an Annualised Run Rate (ARR) of 3,300% from June 2014 and in June 2018, an ARR of £10.4m.
days to go:
Expired
investment:
£3,491,730
The Studio enable members to achieve results through sustainable, structured training. The Studio offer a whole range of sessions such as group classes, one-to-one personal training, spinning and yoga.
days to go:
Expired
investment:
£30,564
Gendius' has created intellin, an application through which people can track diabetes and make a good decision to reduce the risk of diabetes. It is on a mission to make sure that every person with diabetes knows their risk of complications and how to control them. The company has been launched across the EU with over 3,500 downloads in the EU and UK. In 2018, the company won £25K Momentum award to complete UX/UI research and, it has passed ISO27001. Recently, it has been invited to HIMSSHealth2.0 conference for the application's live demo.
days to go:
Expired
investment:
£518,630
Sweat IT is a fitness studio in London, which provides supreme high-intensity training experience with the hardest workouts. The UK fitness industry continues to grow high at a value of over £5 billion because of increasing demand for a healthy lifestyle. Sweat IT redefines this with healthy eating and exercise. The company has the vision to take its business growth to the next level and become the leader of boutique fitness. They have partnered with Gympass, the world’s leading corporate fitness platform to deliver high-intensity fitness classes to London based corporate clients. Till date, they have had over 50,000 class bookings with more than 13,000 Instagram followers and a database of 10,000 customers. The company intends on using the investment for marketing and product branding and next-level growth. They are also looking to fund their second studio in London and have ear-marked a potential site in the City.
days to go:
Expired
investment:
£211,220
Her.9 is a Direct-To-Consumer (DTC) female technology brand that caters to the needs of women during pregnancy. It cites research arguing that up to 40% of women taking prenatal vitamins may not be able to absorb the folic acid within the UK’s leading pregnancy brand. Her.9 aims to resolve this by employing DUOCAP technology. The company asserts that DUOCAP is a capsule-in-capsule delivery system which contains solubilised prebiotics in the outer capsule and probiotics in the inner capsule. The prebiotic releases immediately and the probiotic releases later allowing for targeted supplement delivery in the body. The prenatal supplements market is set to be worth $56 billion globally by 2024. Her.9 aims to be a notable contender in this segment. The company is raising investment to build its already established partnerships and execute its marketing strategy effectively.
days to go:
Expired
investment:
£215,946
PCL Health is a Business-to-Business (B2B) Software-as-a-Service (SaaS) entity that aims to bring hospital-level care to anyone remotely. It asserts that the correct use of remote monitoring can reduce mortality by up to 45%. PCL Health intends to become a contender in the remote healthcare market that is set to touch $30 billion by 2023. It has developed CE rated medical-grade devices that use health algorithms combined with sensors and its proprietary range of apps to allow family members to proactively monitor the health of their loved ones, alongside carers and doctors, remotely. PCL Health has completed two pilots with 65 people and received a Letter Of Intent (LOI) from a National Health Service (NHS) Trust for a clinical trial. It won the 'Innovative Startup' competition at the 2019 Healthcare Unblocked event. PCL Health will use the investment for technology enhancement, running further pilot studies, and working capital.
days to go:
Expired
investment:
£394,680
Aiming to improve the health and well-being of the UK by incorporating spa and beauty treatments into everyday life. PURE is a profitable business that currently runs 8 urban spas across Great Britain, as well as selling their own range of natural products and treatments for skincare to be used at home. Over 100k clients a year have used PURE's services, with 40% of appointments being booked via the company's website and mobile app. This has resulted in sales of £2.9m in 2017, with group revenue increasing by more than 21% in the year-to-date.
Investments will be used to open in more locations, develop more products and expand the PURE Beauty Zone marketplace for independent health and beauty businesses to sell their products in PURE's spas and on their website.
days to go:
Expired
investment:
£72,650
